Physcion increases the sensitivity of hepatocellular carcinoma to sorafenib through miRNA-370/PIM1 axis-regulated glycolysis

Figure 1 Physcion promotes sorafenib sensitivity in in vivo model. A xenograft tumor model was established using the sorafenib-resistant Huh7 cells, followed by treatment with sorafenib and/or physcion. A and B: Tumor growth cure (A) and (B) tumor weight were measured; C: Expression of Ki67 in tumor tissues was analyzed by immunohistochemical staining. ^aP < 0.05 versus control (Cont) group; ^bP < 0.05 versus Cont + SF group. Cont: Control; SF: Sorafenib; phy: Physcion; NS: No significant.